HN2006020928A - "composiciones de tanaproget que contienen etinil estradiol" - Google Patents
"composiciones de tanaproget que contienen etinil estradiol"Info
- Publication number
- HN2006020928A HN2006020928A HN2006020928A HN2006020928A HN2006020928A HN 2006020928 A HN2006020928 A HN 2006020928A HN 2006020928 A HN2006020928 A HN 2006020928A HN 2006020928 A HN2006020928 A HN 2006020928A HN 2006020928 A HN2006020928 A HN 2006020928A
- Authority
- HN
- Honduras
- Prior art keywords
- compositions containing
- estradiol
- containing ethyl
- ethyl estradiol
- tanaproget
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title abstract 3
- 229960005309 estradiol Drugs 0.000 title abstract 3
- 229930182833 estradiol Natural products 0.000 title abstract 3
- PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 title abstract 3
- 229950001471 tanaproget Drugs 0.000 title abstract 3
- 125000001495 ethyl group Chemical class [H]C([H])([H])C([H])([H])* 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 238000009256 replacement therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68880605P | 2005-06-09 | 2005-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2006020928A true HN2006020928A (es) | 2011-02-16 |
Family
ID=37432377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2006020928A HN2006020928A (es) | 2005-06-09 | 2006-06-07 | "composiciones de tanaproget que contienen etinil estradiol" |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20060280800A1 (enExample) |
| EP (1) | EP1893217A2 (enExample) |
| JP (1) | JP5339903B2 (enExample) |
| CN (2) | CN103989687A (enExample) |
| AR (1) | AR057060A1 (enExample) |
| AU (1) | AU2006258048A1 (enExample) |
| BR (1) | BRPI0611250A2 (enExample) |
| CA (1) | CA2610767C (enExample) |
| HN (1) | HN2006020928A (enExample) |
| MX (1) | MX2007015571A (enExample) |
| PE (1) | PE20070001A1 (enExample) |
| TW (1) | TW200716137A (enExample) |
| WO (1) | WO2006135638A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL351083A1 (en) * | 1999-05-04 | 2003-03-10 | American Home Prod | Cyclothiocarbamate derivatives as progesterone receptor modulators |
| MX2007013465A (es) | 2005-04-28 | 2008-01-21 | Wyeth Corp | Tanaproget micronizado, composiciones y metodos para preparar las mismas. |
| DK1874278T3 (da) | 2005-04-28 | 2009-09-28 | Wyeth Corp | Sammensætninger indeholdende mikroniseret tanaproget |
| CN101166736B (zh) * | 2005-04-28 | 2013-02-06 | 惠氏公司 | 他那普戈特的多晶型ⅱ |
| US20060246128A1 (en) * | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget and compositions containing same |
| US20060280800A1 (en) | 2005-06-09 | 2006-12-14 | Wyeth | Tanaproget compositions containing ethinyl estradiol |
| EA201070715A1 (ru) | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции |
| CN103987381B (zh) * | 2011-10-17 | 2017-07-04 | 莱西肯医药有限公司 | (s)‑2‑氨基‑3‑(4‑(2‑氨基‑6‑((r)‑1‑(4‑氯‑2‑(3‑甲基‑1h‑吡唑‑1‑基)苯基)‑2,2,2‑三氟乙氧基)嘧啶‑4‑基)苯基)丙酸乙酯的固体剂型 |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20140006315A1 (en) * | 2012-07-02 | 2014-01-02 | Stèphane Etheve | Method of marketing oregano capsules containing thymoquinone |
| US9326997B2 (en) | 2012-09-24 | 2016-05-03 | Ahlam E. Elakkad | Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014159377A1 (en) * | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6423699B1 (en) * | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
| PL351083A1 (en) * | 1999-05-04 | 2003-03-10 | American Home Prod | Cyclothiocarbamate derivatives as progesterone receptor modulators |
| UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| EP1515725A4 (en) * | 2002-06-25 | 2005-09-21 | Wyeth Corp | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED ILLNESSES |
| WO2004000230A2 (en) | 2002-06-25 | 2003-12-31 | Wyeth | Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders |
| EP1773344A1 (en) * | 2004-07-07 | 2007-04-18 | Wyeth a Corporation of the State of Delaware | Cyclic progestin regimens and kits |
| EP1778710B1 (en) * | 2004-08-13 | 2012-01-18 | Wyeth LLC | Tanaproget derivatives, metabolites, and uses thereof |
| MX2007013465A (es) | 2005-04-28 | 2008-01-21 | Wyeth Corp | Tanaproget micronizado, composiciones y metodos para preparar las mismas. |
| US20060246128A1 (en) | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget and compositions containing same |
| GT200600173A (es) | 2005-04-28 | 2006-11-22 | Forma purificada de tranaproget | |
| CN101166736B (zh) | 2005-04-28 | 2013-02-06 | 惠氏公司 | 他那普戈特的多晶型ⅱ |
| DK1874278T3 (da) | 2005-04-28 | 2009-09-28 | Wyeth Corp | Sammensætninger indeholdende mikroniseret tanaproget |
| US20060280800A1 (en) | 2005-06-09 | 2006-12-14 | Wyeth | Tanaproget compositions containing ethinyl estradiol |
-
2006
- 2006-06-07 US US11/448,965 patent/US20060280800A1/en not_active Abandoned
- 2006-06-07 JP JP2008515878A patent/JP5339903B2/ja not_active Expired - Fee Related
- 2006-06-07 CN CN201410160290.6A patent/CN103989687A/zh active Pending
- 2006-06-07 TW TW095120116A patent/TW200716137A/zh unknown
- 2006-06-07 CA CA2610767A patent/CA2610767C/en not_active Expired - Fee Related
- 2006-06-07 CN CNA200680020195XA patent/CN101193639A/zh active Pending
- 2006-06-07 PE PE2006000630A patent/PE20070001A1/es not_active Application Discontinuation
- 2006-06-07 MX MX2007015571A patent/MX2007015571A/es unknown
- 2006-06-07 EP EP06772444A patent/EP1893217A2/en not_active Ceased
- 2006-06-07 WO PCT/US2006/022150 patent/WO2006135638A2/en not_active Ceased
- 2006-06-07 BR BRPI0611250-1A patent/BRPI0611250A2/pt not_active IP Right Cessation
- 2006-06-07 HN HN2006020928A patent/HN2006020928A/es unknown
- 2006-06-07 AU AU2006258048A patent/AU2006258048A1/en not_active Abandoned
- 2006-06-08 AR ARP060102394A patent/AR057060A1/es not_active Application Discontinuation
-
2011
- 2011-11-09 US US13/292,405 patent/US8664208B2/en not_active Expired - Fee Related
-
2014
- 2014-01-16 US US14/156,863 patent/US20140194398A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1893217A2 (en) | 2008-03-05 |
| MX2007015571A (es) | 2008-03-06 |
| CA2610767A1 (en) | 2006-12-21 |
| US20060280800A1 (en) | 2006-12-14 |
| CN101193639A (zh) | 2008-06-04 |
| BRPI0611250A2 (pt) | 2011-02-15 |
| CA2610767C (en) | 2014-09-23 |
| AR057060A1 (es) | 2007-11-14 |
| US20120114748A1 (en) | 2012-05-10 |
| WO2006135638A2 (en) | 2006-12-21 |
| US20140194398A1 (en) | 2014-07-10 |
| CN103989687A (zh) | 2014-08-20 |
| PE20070001A1 (es) | 2007-01-29 |
| JP5339903B2 (ja) | 2013-11-13 |
| AU2006258048A1 (en) | 2006-12-21 |
| TW200716137A (en) | 2007-05-01 |
| WO2006135638A3 (en) | 2007-03-15 |
| JP2008543758A (ja) | 2008-12-04 |
| US8664208B2 (en) | 2014-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2006020928A (es) | "composiciones de tanaproget que contienen etinil estradiol" | |
| IL173865A0 (en) | System and kit for delivery of restorative materials | |
| BRPI0412659A (pt) | isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto | |
| MX2008002765A (es) | Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos. | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| PE20081506A1 (es) | Formulaciones de ansamicina | |
| BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| GEP20115199B (en) | Phosphatidylinositol 3-kinase inhibitors and their use | |
| UY28572A1 (es) | Compuestos novedosos | |
| CR20140368A (es) | Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036) | |
| ECSP055640A (es) | Composiciones de pirazol útiles como inhibidores de gsk-3 | |
| BR0314356A (pt) | Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas | |
| UY28941A1 (es) | Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso | |
| ECSP088329A (es) | Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 | |
| SE0301700D0 (sv) | Novel compounds | |
| NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
| CL2008001721A1 (es) | Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales. | |
| CY1107906T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου | |
| DK1506185T3 (da) | Forbindelser og deres anvendelse som 5-HT-inhibitorer | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| MX2007011695A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
| ECSP045493A (es) | Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a | |
| EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
| ECSP088270A (es) | Derivados de (indol-3-il)-heterociclo como agonistas del receptor cannabinoide cb1 | |
| CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci |